Detecting Heart Failure Decompensation by Measuring Transthoracic Bioimpedance in the Outpatient Setting: Rationale and Design of the SENTINEL-HF Study by Dovancescu, Silviu et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
University of Massachusetts Medical School Faculty Publications 
2015-10-09 
Detecting Heart Failure Decompensation by Measuring 
Transthoracic Bioimpedance in the Outpatient Setting: Rationale 




Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/faculty_pubs 
 Part of the Biomedical Devices and Instrumentation Commons, Cardiology Commons, Cardiovascular 
Diseases Commons, Diagnosis Commons, Health Services Administration Commons, and the 
Investigative Techniques Commons 
Repository Citation 
Dovancescu S, Saczynski JS, Darling CE, Riistema J, Kuniyoshi FS, Meyer TE, Goldberg RJ, McManus DD. 
(2015). Detecting Heart Failure Decompensation by Measuring Transthoracic Bioimpedance in the 
Outpatient Setting: Rationale and Design of the SENTINEL-HF Study. University of Massachusetts Medical 
School Faculty Publications. https://doi.org/10.2196/resprot.4899. Retrieved from 
https://escholarship.umassmed.edu/faculty_pubs/898 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in University of 
Massachusetts Medical School Faculty Publications by an authorized administrator of eScholarship@UMMS. For 
more information, please contact Lisa.Palmer@umassmed.edu. 
Original Paper
Detecting Heart Failure Decompensation by Measuring
Transthoracic Bioimpedance in the Outpatient Setting: Rationale
and Design of the SENTINEL-HF Study
Silviu Dovancescu1, MSc, MBA; Jane S Saczynski2,3,4, PhD; Chad E Darling5, MD, FACEP; Jarno Riistama1, PhD;
Fatima Sert Kuniyoshi6, PhD; Theo Meyer2, MD, DPhil, FACC; Robert Goldberg2,3,4, PhD; David D McManus2,3,4,
MD, ScM, FACC, FHRS
1Philips Research, Eindhoven, Netherlands
2Department of Medicine, University of Massachusetts Medical School, Worcester, MA, United States
3Department of Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, MA, United States
4Meyers Primary Care Institute, University of Massachusetts Medical School, Worcester, MA, United States
5Department of Emergency Medicine, University of Massachusetts Medical School, Worcester, MA, United States
6Philips Healthcare, Murrysville, PA, United States
Corresponding Author:
Silviu Dovancescu, MSc, MBA
Philips Research







Background: Recurrent hospital admissions are common among patients admitted for acute decompensated heart failure
(ADHF), but identification of patients at risk for rehospitalization remains challenging. Contemporary heart failure (HF) management
programs have shown modest ability to reduce readmissions, partly because they monitor signs or symptoms of HF worsening
that appear late during decompensation. Detecting early stages of HF decompensation might allow for immediate application of
effective HF therapies, thereby potentially reducing HF readmissions. One of the earliest indicators of HF decompensation is
intrathoracic fluid accumulation, which can be assessed using transthoracic bioimpedance.
Objective: The SENTINEL-HF study is a prospective observational study designed to test a novel, wearable HF monitoring
system as a predictor of HF decompensation among patients discharged after hospitalization for ADHF.
Methods: SENTINEL-HF tests the hypothesis that a decline in transthoracic bioimpedance, as assessed daily with the Philips
fluid accumulation vest (FAV) and transmitted using a mobile phone, is associated with HF worsening and rehospitalization.
According to pre-specified power calculations, 180 patients admitted with ADHF are enrolled. Participants transmit daily
self-assessments using the FAV-mobile phone dyad for 45 days post-discharge. The primary predictor is the deviation of
transthoracic bioimpedance for 3 consecutive days from a patient-specific normal variability range. The ADHF detection algorithm
is evaluated in relation with a composite outcome of HF readmission, diuretic up-titration, and self-reported HF worsening (Kansas
City Cardiomyopathy Questionnaire) during a 90-day follow-up period. Here, we provide the details and rationale of
SENTINEL-HF.
Results: Enrollment in the SENTINEL-HF study is complete and the 90-days follow-up is currently under way. Once data
collection is complete, the study dataset will be used to evaluate our ADHF detection algorithm and the results submitted for
publication.
Conclusion: SENTINEL-HF emerged from our long-term vision that advanced home monitoring technology can improve the
management of chronic HF by extending clinical care into patients’ homes. Monitoring transthoracic bioimpedance with the FAV
may identify patients at risk of recurrent HF decompensation and enable timely preventive measures.
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Introduction
Hospitalizations related to acute decompensated heart failure
(ADHF) have increased over recent decades [1], and ADHF is
now the leading cause of hospital admissions in elderly patients
[2]. In light of the high cost related to inpatient treatment of
ADHF [3], there is increasing interest in deploying telehealth
technologies to extend clinical care into the homes of patients
with heart failure (HF), thereby allowing for more frequent
assessment for and prevention of HF decompensations.
However, the identification of HF patients in the early stages
of decompensation remains a major clinical challenge.
Significant efforts have focused on developing HF management
programs to identify and intervene upon patients with or at-risk
for ADHF in order to decrease HF-related hospitalizations [4-7].
Contemporary HF management programs rely on general,
medication-related, and disease-specific patient education as
well as active surveillance for signs or symptoms of acute HF
decompensation. The impact of such programs has been limited,
in part due to their cost, but also because HF surveillance tools,
including measurements of heart rate, blood pressure, and body
weight, show only modest abilities to identify individuals at
risk for HF decompensation. Developing a home-based
monitoring system using markers that can detect ADHF in its
early stages is not only acceptable to elderly patients and
facilitates communication between clinicians and patients, but
has the potential to reduce rates of HF decompensation and
hospitalization.
Novel measures of bioimpedance, or opposition to electric
current through body tissues, can be used to identify fluid
accumulation [8]. Prior studies have demonstrated that
intrathoracic bioimpedance, measured in HF patients with
implantable cardioverter-defibrillators, is a valid predictor of
clinical events including ADHF and hospitalization [9].
Nevertheless, few patients with HF meet criteria for implantation
of implantable cardioverter-defibrillators. More generalizable
and less invasive methods to measure bioimpedance would
capture a more representative population of patients with HF.
Early data suggest that transthoracic bioimpedance measured
using a wearable, investigational device may also detect
intra-thoracic volume retention [10,11] and correlate with
intrathoracic measures [12].
In order to explore the hypothesis that transthoracic
bioimpedance assessed daily with a novel, non-invasive,
wearable fluid accumulation vest (FAV) and transmitted using
a mobile phone would identify patients at risk for HF related
rehospitalization, we designed SENTINEL-HF, a prospective
study of patients discharged after hospitalization for ADHF.
Here, we describe the design and rationale of SENTINEL-HF.
Methods
Device Description
The FAV is a non-invasive wearable monitor designed to
spot-check transthoracic bioimpedance and send the
measurement data to a remote telehealth center. The FAV
system consists of a measurement vest, an electronics module,
a mobile phone-based app, and a remote database (Figure 1).
The measurement vest is a functional textile that is fitted snugly
to the patient’s chest circumference using an adjustment strap
and enables at-home self-measurements [13]. The inside of the
vest has 4 textile electrodes arranged pair wise on 2 supporting
pads located on either side of the rib cage, at the inferior part
of the lungs. The electronics module connects to the back of
the vest. The module determines transthoracic bioimpedance
at multiple frequencies, which enables a model-based assessment
of intra- and extra-cellular fluid status within the thorax [14]
and the detection of respiration [15]. The module also records
a 1-lead ECG as well as the patient’s motion and posture. The
electronics module communicates wirelessly with a mobile
phone-based app that guides the user through the measurement
steps, controls the measurement parameters, and receives the
measurement data. After each measurement, the app
automatically transmits the data to a remote database hosted by
the sponsor in a secure data center.
Self-assessments with the FAV are performed by following a
simple measurement routine that takes 8-10 minutes (Figure 2).
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Figure 1. Components of the fluid accumulation vest (FAV) measurement system and the process for data acquisition, transfer, and storage.
Figure 2. The daily measurement routine consists of wetting the electrodes (eg, using wetted fingertips), connecting the electronics module to the
measurement vest, wearing the vest, sitting down, initiating a measurement with the mobile phone-based app, remaining seated for 5 minutes while the
measurement is in progress, taking the vest off, and docking the devices for charging until the next day’s measurement.
Aim and Design
The aim of the SENTINEL-HF study is to evaluate whether
transthoracic bioimpedance assessed daily using the FAV system
following discharge from an HF hospitalization can predict
recurrent HF decompensation events. The study also aims to
assess patient adherence to the FAV system and delineate
adherence profiles based on novel patient demographic and
psychosocial characteristics.
SENTINEL-HF is a prospective, non-randomized, observational
study. Patients are enrolled during a baseline hospitalization for
HF and are monitored for 45-days post-discharge by means of
daily self-assessments with the FAV. Patient-reported data
related to healthcare utilization and quality of life are collected
through interviews conducted during the baseline hospitalization
and throughout the home monitoring period, at days 7, 14, and
45. Passive surveillance of participants for clinical events is
performed through medical record review for 90 days following
discharge. The extended passive surveillance period enables
the examination of bioimpedance trends in relation with
long-term outcomes.
Approximately 180 patients are enrolled at 2 teaching hospitals
that comprise the University of Massachusetts Memorial
Medical Center (UMMMC), a large academic medical center
in Central Massachusetts. The UMMMC serves a heterogeneous
patient population with a diverse ethnic/racial, socioeconomic,
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urban/rural, and other socio-demographic background. Medicare
30-days readmission and death rates for patients discharged
from an HF-related hospitalization at UMMMC are similar to
the US national rates (23% and 12%, respectively) [16].
Study Population
The SENTINEL-HF study enrolls patients in New York Heart
Association (NYHA) functional classes II-IV who are
hospitalized with a primary diagnosis of HF or with a sign (ie,
vascular congestion on chest radiograph, rales on lung exam,
or peripheral edema) and a symptom (ie, dyspnea or orthopnea)
consistent with ADHF. Adult patients (≥21 years) are eligible
to participate if they are willing and able to comply with the
clinical investigation plan, in particular, able to handle the
technical devices, and are available for follow-up visits
throughout a 45-days post-discharge period. Exclusion criteria
include an N-terminal pro-brain natriuretic peptide
(NT-proBNP) level ≤100 pg/dL, end-stage chronic kidney
disease requiring hemodialysis, chronic obstructive pulmonary
disease (COPD), a primary diagnosis of gastrointestinal bleed,
asthma, cardiac arrest or acute coronary syndrome at baseline,
primary pulmonary hypertension, psychiatric or neurological
disorders of moderate to severe degree, non-English speakers,
pregnant women, prisoners, patients planning to move from
their residence within 2 months from baseline, a body habitus
that prevents the patient from fitting into a measurement vest
or does not allow for adequate electrode-skin contact while
wearing the vest, non-intact skin at the location of the electrodes,
or the presence of an implantable pacemaker/defibrillator.
Endpoints
The ability of the FAV system to predict HF decompensation
events is evaluated in relation to the composite endpoint of
unplanned HF-related rehospitalization and HF worsening. A
rehospitalization is defined as a presentation to the emergency
department or any unplanned admission into a hospital
environment with at least one overnight stay. HF worsening is
defined as either diuretic up-titration or HF-related worsening
quality of life, as assessed by the Kansas City Cardiomyopathy
Questionnaire [17]. Secondary endpoints of the study include
major adverse cardiac events, emergency department visits,
all-cause rehospitalization, and death.
Study Procedures
SENTINEL-HF’s rich data collection is focused on 3 main
activities (home monitoring, interviews, and event tracking),
which are initiated during the baseline hospitalization and
continued up to 90-days post-discharge. The study procedures
are summarized in Figure 3 and are detailed in the following
sections. Data collected during the study is outlined in Table 1.
Figure 3. Diagram of the SENTINEL-HF study. This is a prospective, observational study in patients discharged after a baseline hospitalization for
acute decompensated heart failure (ADHF). Participants will be recruited during the baseline hospitalization and follow-up activities will be initiated
before discharge. Follow-up consists of 3 pillars: home monitoring which includes a period of self-assessments with the fluid accumulation vest (FAV),
participant interviews, and event tracking based on participants’ electronic medical records (EMR).
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Table 1. Data collected in SENTINEL-HF.
Date of collectionDomains and measures










XChief complaint at admission
XICD-9 codes of hospitalization (first 3)
XMedical histories and comorbidities
XType of cardiac dysfunction
XType of ventricular failure





Patient reported outcomes: transition
quality
XXXCare Transitions CTM-319
Patient reported outcomes: quality of
life
XXXSF-12v2™ Health Survey [18]
XXXXKansas City Cardiomyopathy Question-
naire (KCCQ) [17]
XXXXSelf-Care of Heart Failure Index [19]
Psychosocial characteristics
XCapacity of informed consent [20]
XXXXTelephone interview for cognitive status
(TICS) [21]
XXXPatient Health Questionnaire (PHQ-9) [22]
Baseline Procedures
Patients with possible ADHF are identified using a computerized
patient tracking system in the emergency department and by
monitoring hospital admission logs on a daily basis. Screening
is performed based on the diagnosis, chief complaint, and
medical history. The eligibility of potential participants is
confirmed based on their medical record information including
laboratory records, ECG reports, and physical examination
findings. Eligible patients are approached during hospitalization
and provided with information about the study. Patients who
agree to participate sign an informed consent and an
authorization for disclosure of protected health information
during the follow-up period (eg, details of subsequent
readmissions). If study staff have concerns about the capacity
of a potential participant to provide informed consent, an
assessment [20] is conducted to determine the patient’s ability
to express choice, to understand relevant information, and to
appreciate the situation and its likely consequences. Patients
who fail the assessment instrument are ineligible for the study.
Shortly before discharge, each enrolled participant is provided
with a personal FAV monitoring kit consisting of a measurement
vest of appropriate size, an electronics module, a study dedicated
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mobile phone, a manual of operation, and a short form
instructions and troubleshooting guide. Staff adjust the
measurement vest to the participant’s chest circumference
ensuring that the electrodes have good contact with the
participant’s skin, and train participants, and their caregivers
when applicable, to use the study equipment.
Home Monitoring
During a 45-day home monitoring period, participants are
required to perform daily self-assessments with the FAV at a
consistent time of day, preferably upon waking up in the
morning. Study staff use scheduled follow-ups to ensure that
the self-assessments are carried out correctly and, if necessary,
to provide assistance in the form of additional instructions for
using the FAV. On day 1, staff call each enrolled participant to
check on their experience with the first FAV self-assessment.
On day 7, study staff visit the participants at home providing a
booster training for the use of the FAV system. On day 14, study
staff call the participants encouraging them to continue with
the daily self-assessments throughout the following month
(Figure 3). Participants who require additional assistance at any
time during the home monitoring period may call a study hotline
maintained by the sponsor (Philips Healthcare).
Participants’ adherence to the daily self-assessment routine is
monitored based on the data transmitted to the remote database.
Study staff call participants with 2 consecutive missed or
non-evaluable days to identify problems and to provide support
in resuming the daily self-assessments. If 2 consecutive missed
or non-evaluable days continue to occur after the call, study
staff visit the struggling participants at home to troubleshoot
technical issues and to walk the participants through the FAV
self-assessment routine. Participants are removed from the study
if 2 consecutive missed or non-evaluable days continue to occur
after the home visit.
Participant Interviews
In order to identify characteristics associated with the acceptance
and the successful use of the FAV, participant interviews are
conducted in-person or over the telephone at baseline and at
day 7, 14, and 45 post-discharge (Figure 3). During these
follow-up interactions, key patient reported outcomes and
covariates, including severity of depressive symptoms and HF
self-care are assessed. An overview of collected data and
instruments used in the interviews is provided in Table 1.
At each follow-up interview, hospital-to-home transition quality
is assessed using the 3-item Care Transition Measure (CTM3),
an assessment designed to measure the quality of care transitions
from the patient’s perspective [23]. The measure has good
psychometric properties and has predictive validity for
rehospitalizations. We also assess for HF self-management,
patient response to changes in symptoms of HF, and confidence
with self-management using the validated Self-Care for Heart
Failure Index [19]. We measure both general and
disease-specific quality of life at baseline and during each
follow-up interview. General quality of life is measured by
using the Short Form Health Survey SF-12, a validated 12-item
version of the SF-36, a quality of life instrument often used for
patients with heart disease [18]. HF-specific quality of life is
assessed using the Kansas City Cardiomyopathy Questionnaire
(KCCQ) [17].
Each participant’s psychosocial profile is characterized for a
better understanding of factors associated with successful FAV
use. Cognitive impairment and depressive symptoms are
assessed at baseline and during each follow-up interview using
the telephone interview for cognitive status (TICS) [21] and the
9-item Patient Health Questionnaire (PHQ-9) [22], respectively.
We also gather information about clinical endpoints, including
medication changes, doctor’s visits, emergency department
visits, or readmissions. These reports are confirmed and
extended by reviewing each participant’s medical record.
Baseline Clinical Characteristics and Endpoint Review
Clinical information (medical history, physical exam data, chest
x-ray findings, and serum laboratory values) and demographics
(age, gender, marital status, race/ethnicity, height, weight, and
blood pressure and heart rate) are abstracted at baseline from
the participants’ electronic medical records. Surveillance of
participants continues for 90 days post-discharge by reviewing
all additional clinical data including hospitalizations or physician
visits related to possible ADHF, cardiac studies, consultations,
discharge summaries, emergency service records, lab reports,
office and clinic notes, operative and procedure reports, problem
lists, pulmonary studies, and radiology results from the
electronic medical records. Because the majority (80-90%) of
patients hospitalized for ADHF at UMMMC follow-up with a
UMMMC cardiologist and are rehospitalized at UMMMC, the
vast majority of participant data is available in one centralized
database of electronic medical records. Information related to
patient-reported clinical events occurring outside the UMMMC
health system is obtained from the respective healthcare provider
based on the participant’s consent for solicitation of outside
records. Endpoints are adjudicated on a rolling basis by 3 expert
physicians (authors TEM, DDM, CD) blinded to FAV measures
and clinical outcomes.
Data Analysis
The study database is used to evaluate the performance of a
previously developed ADHF detection algorithm informed by
bioimpedance measures.
Parameter Extraction
Relevant tissue characteristics are extracted from each FAV
self-assessment by fitting the Cole-Cole model (Figure 4) to
the multifrequency bioimpedance data collected by the device
[14,24]. The model parameters reflect extracellular fluids (RE),
intracellular fluids (R∞), tissue relaxation (fc), and tissue
heterogeneity (α). Thoracic fluid accumulation due to worsening
HF directly affects the value of RE which is expected to decrease
[8,11]. Therefore, RE will be used as the primary bioimpedance
index to predict HF decompensation.
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Figure 4. Cole-Cole model equation.
Acute Decompensated Heart Failure (ADHF) Detection
An ADHF detection algorithm was designed to monitor the
daily evolution of a patient’s bioimpedance index. The algorithm
determines if a new value is normal by comparing it to a
patient-specific range of normal variability. The occurrence of
abnormal values of the bioimpedance index causes the algorithm
to raise decompensation alerts. In a real-life use case,
decompensation alerts have the potential to prevent HF events,
for example hospitalizations, only if they are raised a sufficient
number of days prior to an acute decompensation allowing
sufficient time for healthcare providers to intervene and for
administered therapies to take effect. Because telehealth alerts
are generally reviewed during business hours on weekdays, the
reaction to an alert may be delayed by 2-3 days if an alert is
raised at the beginning of a weekend. To accommodate for this
in the evaluation of the ADHF detection algorithm we define
the actionable period (AP) as the time window preceding an
endpoint in which decompensation alerts are most likely to
contribute to an improved patient outcome. The algorithm is
evaluated based on its ability to raise alerts within the AP and
any alert raised after the AP is excluded from the performance
evaluation (Figure 5). The length and the end of the AP can be
set by each healthcare provider individually. While healthcare
providers generally agree that a realistic length for the AP is
likely to be shorter than 30 days, setting the end of the AP
remains a topic of debate. Therefore, we set the boundaries of
the AP based on the performance achieved by current standard
of care telehealth systems which include measurements of
weight, heart rate, or blood pressure. These systems typically
use weight as the primary predictor of decompensation and have
the ability to raise decompensation alerts 2-3 days prior to an
impending HF-related hospitalization [25]. In the analysis of
the SENTINEL-HF study, we evaluate whether the FAV is able
to extend this period by enabling earlier decompensation alerts.
To this aim, we vary the end of AP down to 2 days prior to an
endpoint event and the length of the AP between 10 and 30
days.
The predictive accuracy of the ADHF detection algorithm is
assessed based on the number of true positive, true negative,
false positive and false negative alerts preceding an endpoint.
Prediction performance metrics are assessed in relation with
the primary and the secondary endpoints, respectively.
Figure 5. The ADHF detection strategy. Example of an ADHF hospitalization occurring during the FAV monitoring period. The ADHF detection
algorithm is evaluated based on its ability to raise decompensation alerts within an actionable period which ends days prior to the event.
Sample Size Calculations
Our prospective sample size calculations were guided by the a
priori assumption that the FAV would have a sensitivity of 0.75
to detect a primary endpoint of ADHF hospitalization. This
assumption was based on a previous dataset collected for the
development of our ADHF detection algorithm [12]. In
SENTINEL-HF, we plan to have 107 patients complete the
study period and adhere to the FAV daily over 45-days to
exclude a real sensitivity lower than 0.60. To account for
non-evaluable data and a 30% dropout rate, we require a
minimum of 160 participants to provide a 0.1 95% confidence
interval around an observed sensitivity of 0.75. We are
employing an adaptive study design with interim sample size
re-assessments based on the observed drop-out rate,
non-evaluable data, and the number of ADHF events.
Ethical Conduct and Study Management
The SENTINEL-HF study is conducted in compliance with
Good Clinical Practice and the principles outlined by the
Declaration of Helsinki. The study has been approved by the
Committee for the Protection of Human Subjects at University
of Massachusetts Medical School with Institutional Review
Board number H00001760. All study participants provide
written informed consent at enrollment. The study is sponsored
by Philips Healthcare and is monitored by the sponsor in
compliance with the Code of Federal Regulations. Unanticipated
adverse device effects are reported to the sponsor and to the
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Massachusetts Medical School Institutional Review Board. The
study trial registration number is NCT01877369.
Results
SENTINEL-HF enrolled the first patient in June 2013 and the
last patient in April 2015. A total of 180 patients are enrolled
in the study. Once the 90-days follow-up of the last patient is
complete, the SENTINEL-HF dataset will be used to evaluate
our ADHF detection algorithm and first results will be submitted
for publication.
Discussion
The SENTINEL-HF study is a prospective, non-randomized,
observational study evaluating the ability of a wearable HF
monitor to anticipate ADHF events. Patients perform daily
self-assessments of transthoracic bioimpedance for 45 days
following discharge from a HF hospitalization. Patient-reported
quality of life are assessed using validated questionnaires and
clinical events are abstracted from the patients’ electronic
medical records. Endpoints adjudicated by a team of physicians
are used to evaluate the performance of an ADHF detection
algorithm informed by serial bioimpedance measurements.
SENTINEL-HF supports our long term vision that advanced
home monitoring technology can aid the management of chronic
HF by extending clinical care into patients’ homes, thereby
preventing HF decompensations and reducing hospitalizations.
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